The size of the Europe HbA1c Testing market is anticipated to grow at 11.32% CAGR from 2021 to 2026. It is estimated that the Europe market was valued at USD 356.22 Million in 2021 and is expected to reach USD 608.96 Million by 2026.
HbA1c is a modified form of an oxygen carrying pigment present in red blood cells called hemoglobin. Most of the hemoglobin is in HbA form but a small fraction transforms into HbA1 during their lifespans. On further findings it was discovered in 1950s by the scientists that HbA1 could further be separated into HbA1a, HbA1b, and HbA1c. Patients suffering from diabetes have an alarming high level of HbA1c present in their body as its formation occurs only during a process called glycosylation which involves the conversion of glucose into glycogen for storage purpose.
The number of people affected by diabetes is rising exponentially with every passing day due to poor dietary choices coupled with lack of physical activities and high levels of stress. As a result, physicians are increasingly prescribing HbA1c test to their patients, which in turn is expected to drive the market revenue for HbA1c Testing. Moreover, emergence of point of care and other new devices to lower the cost of diabetes testing is further expected to aid the market growth
The Europe HbA1c Testing market is segmented on the basis of Type, Technology and End User. On the basis of Type, the market is segmented into Hand Held Devices, and Bench Top Devices. In 2017, bench top devices led the type segment of the market due to its fast and accurate results. On the basis of technology, the market is segmented into Ion Exchange High-performance liquid chromatography, Enzymatic Assay, Affinity Binding Chromatography Turbidimetric Inhibition Immunoassay and Other. Increasing investment is key factor responsible for the dominance of affinity binding chromatography segment. On the basis of End User, the market is segmented into Hospital, Home Care, Diagnostic laboratory, and Research Institution. Rising popularity of home care services is a key factor governing this segments growth.
On the basis of geography, the HbA1c Testing market is segmented into Germany, Italy, France, Spain and UK. Europe accounted for the second largest share of the market.
Some of the key players operating in the market are like Transasia Biomedicals ltd., Abbott Laboratories, Alere, Inc., Arkray, Inc., Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare and Trinity Biotech plc.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Technology
5.1.1 Introduction
5.1.2 Ion-Exchange HPCL
5.1.3 Enzymatic Assay
5.1.4 Affinity Binding Chromatography
5.1.5 Turbidimetric Inhibition Immunoassay
5.1.6 Other
5.1.7 Y-o-Y Growth Analysis, By Technology
5.1.8 Market Attractiveness Analysis, By Technology
5.1.9 Market Share Analysis, By Technology
5.2 Type
5.2.1 Introduction
5.2.2 Hand Held Devices
5.2.3 Bench Top Devices
5.2.4 Y-o-Y Growth Analysis, By Type
5.2.5 Market Attractiveness Analysis, By Type
5.2.6 Market Share Analysis, By Type
5.3 End User
5.3.1 Introduction
5.3.2 Hospital
5.3.3 Home Care
5.3.4 Diagnostic laboratory
5.3.5 Research Institution
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Technology
6.1.3.3 By Type
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Technology
6.1.4.3 By Type
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Technology
6.1.5.3 By Type
6.1.5.4 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Transasia Biomedicals ltd.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Abbott Laboratories
8.3 Alere Inc.
8.4 Arkray Inc.
8.5 Bio-Rad Laboratories Inc.
8.6 Danaher Corporation
8.7 F. Hoffmann-La Roche Ltd.
8.8 Siemens Healthcare
8.9 Trinity Biotech plc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
